ZyVersa Therapeutics Files 8-K on Board Changes and Shareholder Votes

Ticker: ZVSA · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1859007

Zyversa Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyZyversa Therapeutics, Inc. (ZVSA)
Form Type8-K
Filed DateJun 12, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation, corporate-governance

TL;DR

ZyVersa's 8-K: Board shakeup, new exec pay, and shareholder votes are in. Check it.

AI Summary

ZyVersa Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements. The filing also covers matters submitted to a vote of security holders and includes financial statements and exhibits. The company was formerly known as Larkspur Health Acquisition Corp. and changed its name on April 26, 2021.

Why It Matters

This filing provides crucial updates on the company's leadership and governance, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can signal shifts in company strategy or internal dynamics that may affect future performance.

Key Players & Entities

  • ZyVersa Therapeutics, Inc. (company) — Registrant
  • Larkspur Health Acquisition Corp. (company) — Former company name
  • June 11, 2025 (date) — Earliest event reported
  • June 12, 2025 (date) — Date of report
  • April 26, 2021 (date) — Date of name change

FAQ

What specific changes were made to the board of directors?

The filing indicates the departure of directors and the election of new directors, but the specific names and details of these changes are not provided in the excerpt.

What are the details of the compensatory arrangements for certain officers?

The filing mentions compensatory arrangements for certain officers as an item of disclosure, but the specific details of these arrangements are not included in the provided text.

What matters were submitted to a vote of security holders?

The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not specified in the excerpt.

When did ZyVersa Therapeutics, Inc. change its name from Larkspur Health Acquisition Corp.?

ZyVersa Therapeutics, Inc. changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.

What is the primary business of ZyVersa Therapeutics, Inc. according to the filing?

ZyVersa Therapeutics, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.